Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VALEANT PHARMACEUTICALS INTL INC T.VRX

Healthcare Drug Manufacturers - Specialty & Generic
"Valeant Pharmaceuticals is a global specialty pharmaceutical firm with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The firm also has a branded generics business that operates primarily in Latin America, Eastern Europe, and Asia."


TSX:VRX - Post by User

VALEANT PHARMACEUTICALS INTL INC > No, Valeant Is Not 'A Steal'
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by deeppocket83on Dec 15, 2016 5:24pm
79 Views
Post# 25607013

RE:No, Valeant Is Not 'A Steal'

RE:No, Valeant Is Not 'A Steal'These articles are rubbish. Have a listen to the BMO conference. Joe has said a lot of great things for next year. Launching more generics. Fighting generics by price matching at Wallgreens. Broadalumab will be launched in Feb. All the debt for 2017 is paid off, so no debt payments for next year. 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities